AU2002239748A1 - Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia - Google Patents

Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia

Info

Publication number
AU2002239748A1
AU2002239748A1 AU2002239748A AU3974802A AU2002239748A1 AU 2002239748 A1 AU2002239748 A1 AU 2002239748A1 AU 2002239748 A AU2002239748 A AU 2002239748A AU 3974802 A AU3974802 A AU 3974802A AU 2002239748 A1 AU2002239748 A1 AU 2002239748A1
Authority
AU
Australia
Prior art keywords
derivatives
metabolites
tocopherol
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002239748A
Inventor
Sekhar Boddupalli
Lesley A. Brown
Ughetta Del Balzo
Stephen Flaim
Guy Michael Miller
Bing Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galileo Pharmaceuticals Inc
Original Assignee
Galileo Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galileo Laboratories Inc filed Critical Galileo Laboratories Inc
Publication of AU2002239748A1 publication Critical patent/AU2002239748A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002239748A 2000-12-15 2001-12-14 Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia Abandoned AU2002239748A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US25626900P 2000-12-15 2000-12-15
US60/256,269 2000-12-15
US29658101P 2001-06-06 2001-06-06
US29658001P 2001-06-06 2001-06-06
US60/296,580 2001-06-06
US60/296,581 2001-06-06
US34357501P 2001-10-19 2001-10-19
US60/343,575 2001-10-19
PCT/US2001/050984 WO2002047680A2 (en) 2000-12-15 2001-12-14 Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia

Publications (1)

Publication Number Publication Date
AU2002239748A1 true AU2002239748A1 (en) 2002-06-24

Family

ID=27500564

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002239748A Abandoned AU2002239748A1 (en) 2000-12-15 2001-12-14 Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia

Country Status (4)

Country Link
US (1) US20020132845A1 (en)
AU (1) AU2002239748A1 (en)
CA (1) CA2430415A1 (en)
WO (1) WO2002047680A2 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
DE60140141D1 (en) * 2000-11-14 2009-11-19 Vital Health Sciences Pty Ltd Compositions comprising complexes of tocopherol phosphate derivatives
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
EP1420797A4 (en) 2001-07-27 2005-03-02 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
US20040152764A1 (en) * 2001-12-14 2004-08-05 Miller Guy M. Compositions and methods for the prevention and treatment of cerebral ischemia
US20050220753A1 (en) * 2002-03-22 2005-10-06 Beijing Jiankai Technology Co., Ltd Hydrophilic polymers-flavoids conjugates and pharmaceutical compositions comprising them
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
FR2844716B1 (en) * 2002-09-23 2008-11-21 Marcel Jacques Chicouri NOVEL PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR FOR FOOD HYGIENE OF DIABETICS
EP1558922B1 (en) * 2002-10-30 2013-02-27 Ampere Life Sciences, Inc. Identifying therapeutic compounds based on their physical-chemical properties
US7470798B2 (en) 2003-09-19 2008-12-30 Edison Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
ATE548022T1 (en) * 2003-11-17 2012-03-15 Sederma Sa COMPOSITIONS CONTAINING A COMBINATION OF TETRAPEPTIDES AND TRIPEPTIDES
WO2005084678A1 (en) * 2004-03-03 2005-09-15 Vital Health Sciences Pty Ltd Alkaloid formulations
US8298169B2 (en) * 2004-03-22 2012-10-30 Vahe Stephan Yacoubian System, methods and apparatus for cerebral protection
CA2564066A1 (en) 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
EP1621201A1 (en) * 2004-07-28 2006-02-01 NeuroCode AG Hesperidin for prophylaxis and treatment of diseases of the central nervous system, in particular Alzheimer's and Parkinson's diseases, for therapy after stroke as well as for chronic pain.
KR101238703B1 (en) * 2004-08-03 2013-03-04 바이탈 헬스 사이언시즈 피티와이 리미티드 Carrier for enteral administration
US7837650B1 (en) 2004-12-30 2010-11-23 Advanced Cardiovascular Systems, Inc. Method and apparatus to prevent reperfusion injury
EP1858508A4 (en) * 2005-03-03 2009-01-07 Vital Health Sciences Pty Ltd Compounds having anti-cancer properties
US20090239827A1 (en) * 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
DK1888059T3 (en) 2005-06-01 2015-03-30 Edison Pharmaceuticals Inc Redox-active therapeutic products for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers
ES2557475T3 (en) 2005-06-17 2016-01-26 Vital Health Sciences Pty Ltd. A carrier comprising one or more di- and / or monophosphate derivatives of electron transfer agents
EP2368442B1 (en) 2005-07-27 2014-12-17 Symrise AG Use of hesperetin for enhancing the sweet taste
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
US9533127B2 (en) * 2006-07-24 2017-01-03 Abbott Cardiovascular Systems Inc. Methods for inhibiting reperfusion injury
US20120059254A1 (en) * 2007-03-14 2012-03-08 Wang Lifan Apparatus and method for phase-space reduction for imaging of fluorescing, scattering and/or absorbing structures
US8628490B2 (en) * 2007-05-17 2014-01-14 Vahe Stephan Yacoubian System, methods and apparatus for cerebral protection
US9029322B2 (en) * 2007-06-05 2015-05-12 Cornell University Compounds for enhancing p21 expression and methods of use thereof
US20100247680A1 (en) * 2007-06-15 2010-09-30 Csaba Szabo Compositions and Methods to Modulate Angiogenesis
EP3018122B1 (en) 2007-11-06 2018-10-10 BioElectron Technology Corporation 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EA023618B1 (en) * 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. (HET)ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
JP5710277B2 (en) 2008-03-05 2015-04-30 エジソン ファーマシューティカルズ， インコーポレイテッド 2-Substituted-p-quinone derivatives for the treatment of oxidative stress diseases
WO2009158348A1 (en) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
BRPI1013376A8 (en) 2009-04-28 2017-07-11 Edison Pharmaceuticals Inc USE OF TOCOTRIENOL QUINONES, PHARMACEUTICAL PREPARATION INCLUDING SAID QUINONES AND USE OF THEM
EP2470168B1 (en) * 2009-08-26 2018-01-31 BioElectron Technology Corporation Methods for the prevention and treatment of cerebral ischemia
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
ES2829386T3 (en) 2010-03-30 2021-05-31 Phosphagenics Ltd Transdermal administration patch
US20130337453A1 (en) * 2010-10-21 2013-12-19 Tufts University Extracellular mitochondria-based screening and treatment
EP2685992A4 (en) 2011-03-15 2014-09-10 Phosphagenics Ltd Amino-quinolines as kinase inhibitors
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
CN103405408B (en) * 2013-06-27 2015-11-11 天津医科大学总医院 The application of chrysin in treatment ischemic cerebral apoplexy Chinese medicine
CN103877075B (en) * 2014-03-21 2016-01-06 贾正平 Chrysin is preparing the application in anti-anoxic medicine
CN104926769B (en) * 2014-03-21 2018-12-04 景临林 The synthetic method of 7- ethoxy Chrysin and its preparing the application in anti-anoxic medicine
US10465229B2 (en) 2014-05-27 2019-11-05 Case Western Reserve University System and method for detecting neural injury
WO2016090373A1 (en) * 2014-12-05 2016-06-09 Case Western Reserve University Compositions and methods of modulating s-nitrosylation
US11426386B2 (en) 2014-12-05 2022-08-30 Case Western Reserve University Compositions and methods of modulating S-nitrosylation
WO2019060720A1 (en) 2017-09-25 2019-03-28 Case Western Reserve University Compositions and methods of reducing serum cholesterol and pcsk9
EP3233786B1 (en) 2014-12-16 2022-03-16 PTC Therapeutics, Inc. Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
CN110662733A (en) 2016-12-21 2020-01-07 埃维科生物技术有限公司 Method of producing a composite material
US11931339B2 (en) 2018-06-25 2024-03-19 Case Western Reserve University Compositions and methods for treating tissue injury
JP2022502368A (en) 2018-09-21 2022-01-11 ケース ウエスタン リザーブ ユニバーシティ Aldoket reductase inhibitor and its use
US11697807B2 (en) 2019-09-30 2023-07-11 Case Western Reserve University Electrochemical biosensor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5818374A (en) * 1981-07-27 1983-02-02 Nitsusui Seiyaku Kk Eicosapentaenoic acid tocopherol ester
JPS60197621A (en) * 1984-03-19 1985-10-07 Hohnen Oil Co Ltd Hypocholesterolemic
DK36389A (en) * 1988-02-05 1989-08-06 Eastman Kodak Co PREPARATION AND PROCEDURE FOR PREVENTION OF REFUSION
US5139796A (en) * 1991-06-28 1992-08-18 Wm. Wrigley Jr. Company Tocopherol mixture for use as a mint oil antioxidant in chewing gum
US20020165270A1 (en) * 1997-05-13 2002-11-07 Jose Remacle Use of a pharmaceutical composition for treating and/or preventing ischemia
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6346544B2 (en) * 2000-03-02 2002-02-12 Oklahoma Medical Research Foundation Desmethyl tocopherols for protecting cardiovascular tissue

Also Published As

Publication number Publication date
WO2002047680A2 (en) 2002-06-20
WO2002047680A3 (en) 2003-03-27
US20020132845A1 (en) 2002-09-19
WO2002047680A9 (en) 2003-10-09
CA2430415A1 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
AU2002239748A1 (en) Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
AU2002340999A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
AU2002239282A1 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
AU2682401A (en) Flavonoid drug and dosage form, its production and use
AU2001235691A1 (en) Use of paullone derivatives for making medicines
AU2001282267A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
AU2001262318A1 (en) Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament
AU2002216311A1 (en) Surgical reamer
AU2002246515A1 (en) Medicated tattoos
AU2001284021A1 (en) Quinazoline derivatives, medicaments containing these compounds, their use, and methods for the production thereof
AU2001276860A1 (en) Medicaments for chemotherapeutic treatment of disease
AU2001262221A1 (en) Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use
AU2922600A (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
AU2001264042A1 (en) 1,4-diazabicyclo(3.2.2)nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
AU2001264044A1 (en) 1,4-diazabicyclo(3.2.2)nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
AU2003269018A1 (en) Acylaminothiazole derivatives, preparation and therapeutic use thereof
AU2001243515A1 (en) Combination drug therapy
AU2000263864A1 (en) Tissue specific prodrug
AU2002233407A1 (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof
AU2001214116A1 (en) Novel paclitaxel derivatives for the treatment of cancer
AU6866500A (en) Chromone derivatives, process for the preparation of the same and uses thereof
HUP0201810A3 (en) Sootepenseone and its derivatives, their preparation and use as medicament
AU6846500A (en) Novel 8-carbonyl chroman derivatives, preparation and therapeutic use thereof
AU2002218750A1 (en) Photoactivated drug therapy
AU2001234270A1 (en) Bandage for orthopaedic use